Long COVID Brain Scans Reveal Damage to Dopamine Neurons
Brain imaging scans have uncovered direct evidence that long COVID is associated with measurable injury to dopamine-releasing neurons in the brain, offering a biological explanation for persistent symptoms such as chronic fatigue, slowed movement, memory loss, and a lack of motivation. Published in the journal eBioMedicine, the research used positron emission tomography (PET) to track dopamine nerve terminal density in patients experiencing neurological complications months after their initial viral infection.
- Researchers at the Centre for Addiction and Mental Health used PET imaging to discover that long COVID patients exhibit significantly lower levels of dopamine imaging markers in the striatum.
- The specific loss of dopamine-releasing neurons directly correlates with patient symptoms, linking ventral striatum reductions to motivational deficits and putamen changes to motor slowing.
- The findings establish that neuroinflammation from the initial SARS-CoV-2 infection can lead to lasting structural changes in the brain’s dopamine system, opening potential pathways for targeted therapeutic repurposing.
Positron Emission Tomography Scans Identify Dopamine Neuron Loss in Long COVID Patients
Affecting approximately five percent of the global population, long COVID frequently traps individuals in a debilitating cycle of cognitive impairment, physical exhaustion, and affective changes lasting three months or longer post-infection. While epidemiological tracking estimates that the condition impacts roughly two million people in Canada and nine million adults in the United States, clinicians have lacked definitive diagnostic markers to explain the underlying pathophysiology. According to findings detailed by researchers at the Centre for Addiction and Mental Health (CAMH), brain scans now confirm that structural damage to the central nervous system’s dopamine pathways plays a major role.
To evaluate neural integrity, investigators utilized positron emission tomography (PET), a specialized imaging method that maps active biological processes inside the living human brain. The study measured a well-established marker of dopamine neuron health across a cohort of long COVID participants, comparing those metrics against scans gathered from healthy control subjects. The data revealed that individuals with long COVID possess significantly reduced levels of the dopamine imaging marker throughout all major subsections of the striatum, pointing to a direct loss of dopamine nerve terminal density.
Mapping Specific Neurotransmitter Deficits to Clinical Symptoms
The imaging data yielded precise correlations between the location of neural injury and the distinct clinical complaints reported by patients. Reductions in the ventral striatum mapped directly to a pronounced loss of motivation and apathy. Diminished marker levels in the dorsal putamen corresponded with objective motor slowing, while lower concentrations in the caudate putamen tracked closely with persistent memory difficulties. This regional specificity moves clinical understanding beyond generalized malaise, demonstrating that localized damage within distinct dopaminergic networks drives specific neurological deficits.
Dr. Jeffrey Meyer, senior author of the study, Canada Research Chair, and Senior Scientist at the Brain Health Imaging Centre, points out that this particular category of cellular damage commonly results in motor and motivational impairments in alternative medical contexts. "This kind of injury is well known to produce symptoms like lack of motivation and motor slowing, and may contribute to memory difficulties in other neurological conditions.”
Connecting Brain Inflammation to Long-Term Dopamine System Damage
This latest discovery builds directly upon earlier research conducted by the same team at CAMH, which documented elevated levels of neuroinflammation in the brains of long COVID patients, particularly within regions densely populated by dopamine-producing neurons. Because chronic inflammation is a known catalyst for neuronal injury across various neurodegenerative contexts, the new PET data bridges the gap between acute immune activation and chronic structural damage.
The correlation between localized inflammation, reduced marker density, and clinical severity reframes long COVID not merely as a lingering systemic inflammatory state, but as a condition that actively disrupts central neurotransmitter regulation. This pathological shift has immediate therapeutic implications. Several pharmacological agents already approved for other neurological disorders function explicitly by increasing dopamine availability or enhancing synaptic signaling. Investigators suggest that repurposing existing dopamine precursors or medications that inhibit dopamine metabolism could offer a viable strategy for mitigating persistent cognitive dysfunction.
As academic medical centers continue to investigate the pathophysiological mechanisms of post-viral syndromes, these imaging revelations provide crucial biological validation for millions of individuals living with chronic neurological symptoms. Future clinical trials focusing on dopaminergic pathways will ultimately determine whether restoring neurotransmitter signaling can reverse these persistent deficits.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*
Worth a look